Baker Bros. Advisors LP Ultragenyx Pharmaceutical Inc. Transaction History
Baker Bros. Advisors LP
- $9.86 Billion
- Q2 2025
A detailed history of Baker Bros. Advisors LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 2,772,692 shares of RARE stock, worth $77.9 Million. This represents 1.02% of its overall portfolio holdings.
Number of Shares
2,772,692
Previous 1,576,114
75.92%
Holding current value
$77.9 Million
Previous $57.1 Million
76.65%
% of portfolio
1.02%
Previous 0.68%
Shares
7 transactions
Others Institutions Holding RARE
# of Institutions
361Shares Held
89.7MCall Options Held
3.61MPut Options Held
2.08M-
Vanguard Group Inc Valley Forge, PA10.2MShares$287 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$158 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.94MShares$111 Million0.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.89MShares$81.1 Million0.01% of portfolio
-
State Street Corp Boston, MA2.57MShares$72.3 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $1.97B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...